Search

Maralice Conacci-Sorrell, Ph.D., Associate Professor of Cell Biology at UT Southwestern Medical Center, is the recipient of the 2026 Mary Beth Maddox Award and Lectureship from the Texas Academy of Medicine, Engineering, Science & Technology (TAMEST).

UT Southwestern Medical Center ranked fourth in the nation and No. 1 in Texas for commercializing new biomedical technologies, considered a critical step in bringing its laboratory discoveries into clinical practice.

A new initiative funded by The University of Texas System and the state of Texas seeks to improve care for trauma patients.

Interstitial pneumonia with autoimmune features (IPAF) is a disease with many possible causes and no standard of care, making it particularly difficult to treat. While immunosuppressant drugs are primarily prescribed, they don’t work for all patients.

Catherine Spong, M.D., Chair and Professor of Obstetrics and Gynecology at UT Southwestern Medical Center, has been elected to the National Academy of Medicine (NAM) in recognition of her significant impact on the field of maternal-fetal medicine, her leadership in women’s health research, and her

At exactly 11 a.m. Friday, surrounded by family, friends, and mentors, 224 members of UT Southwestern Medical School’s Class of 2024 – who all embarked on their medical education during the height of the COVID-19 pandemic – learned where they will continue their medical training.

Delivering genetic material tagged with a cellular “ZIP code” prompted cells to secrete proteins or drugs into the bloodstream that successfully treated psoriasis and cancer in mouse models, UT Southwestern Medical Center scientists report in a new study.

In Memoriam: Jonathan W. Uhr, M.D., renowned immunologist and longtime Chair of Microbiology

Two genes working in tandem play a critical role in shaping the identity and behavior of prostate cancer cells and their response to treatment, UT Southwestern Medical Center researchers report.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).